Cannara Biotech (TSXV:LOVE) Valuation Rank

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cannara Biotech Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

LOVFF:USA 8CB0:Germany

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Executives

Nicholas Sosiak	Senior Officer
Donald John Olds	Director
Olymbec Investments Inc.	10% Security Holder
Derek Elan Stern	Director
Scott Carroll	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot	Director, Senior Officer
Brian Sherman	Senior Officer
Avi Krivorot	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer	Senior Officer
Jack M. Kay	Director
Donal Carroll	Director or Senior Officer of 10% Security Holder